Translational Research Program To Advance Clinical Outcomes In Acute Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$418,192.00
Summary
Five-year survival in acute myeloid leukaemia (AML) is only 27%, placing it amongst the worst-ranked cancers for clinical outcome. Improved patient outcomes will be achieved through implementation of a Translational Research Program to support novel agent drug testing, early-phase and randomised clinical trials and a national clinical registry to audit outcomes. New insights into leukaemic stem cell function and mechanisms of drug resistance will inform the design of future clinical trials.
The Generation Of High Quality Evidence In Critical Care Medicine Through Multicentre Randomized Controleld Trials And Its Translation Into Practice
Funder
National Health and Medical Research Council
Funding Amount
$240,121.00
Summary
This research program will establish new approaches to sepsis, traumatic brain injury, kidney protection, transfusion, post-operative care, sedation, antibiotics and mobilization of acutely ill patients. Experimental research will help understand why the kidney malfunctions during severe infection. Database investigations will identify of successful patterns of treatment and potential new fields of investigations. Informatics based studies will use electronic data to develop decision support sys ....This research program will establish new approaches to sepsis, traumatic brain injury, kidney protection, transfusion, post-operative care, sedation, antibiotics and mobilization of acutely ill patients. Experimental research will help understand why the kidney malfunctions during severe infection. Database investigations will identify of successful patterns of treatment and potential new fields of investigations. Informatics based studies will use electronic data to develop decision support systems to improve patient care.Read moreRead less
Using Mouse Models To Identify Better Therapies For Acute Leukemia And Myelodysplasia
Funder
National Health and Medical Research Council
Summary
Despite great advances in the understanding of the genes that cause cancers of the blood, cure rates for patients with acute leukemia, or a more indolent form called myelodyspslaia, has not improved significantly over the last 20 years, with the majority of patients dying from resistant or recurrent disease within 5 years. Our research will use mouse models of acute leukemia and myelodysplasia to identify the critical genetic pathways that drive these diseases and to design and test new therapie ....Despite great advances in the understanding of the genes that cause cancers of the blood, cure rates for patients with acute leukemia, or a more indolent form called myelodyspslaia, has not improved significantly over the last 20 years, with the majority of patients dying from resistant or recurrent disease within 5 years. Our research will use mouse models of acute leukemia and myelodysplasia to identify the critical genetic pathways that drive these diseases and to design and test new therapies that can be taken into clinical trials.Read moreRead less